Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis
Conditions
Interventions
TAK-906 Maleate
Placebo
Locations
109
United States
Digestive Health Specialists of the Southeast
Dothan, Alabama, United States
Del Sol Research Management
Tucson, Arizona, United States
Del Sol Research Management
Tucson, Arizona, United States
GW Research
Chula Vista, California, United States
Trial Connections - New Hope Research Development
Corona, California, United States
Paragon Rx Clinical - Garden Grove
Garden Grove, California, United States
Start Date
October 14, 2018
Primary Completion Date
June 14, 2021
Completion Date
July 15, 2021
Last Updated
November 16, 2022
NCT07324785
NCT04254549
NCT04028492
NCT06340828
NCT04208698
NCT03268941
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions